Drug recall · November 2, 2022
Fondaparinux Sodium Injection recall
Why: Subpotent Drug: Out of specification for assay
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520. Made in India. NDC 55150-232-10 (carton)NDC 55150-232-00 (syringe)
- Lots / codes
Lot # CFN200020, EXP Nov. 2022
- Quantity
- 11,520 units
- Company
- AuroMedics Pharma LLC, East Windsor, NJ
- Distribution
- Nationwide in the USA
- Initiated
- September 30, 2022 · Voluntary: Firm initiated
- Classified
- October 24, 2022
- Reported
- November 2, 2022
- Ended
- September 18, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Fondaparinux
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.